This presentation describes the MMV artemisinin combination therapies currently (at the date of the symposium) in Phase III clinical trials (i.e. dispersible artemether-lumefantrine, dihydroartemisinin-piperaquine, chlorproguanil-dapsone-artesunate and pyronaridine-artesunate), and what sponsors want from these drugs in Phase IV, post-marketing (i.e. information about safety, and their usefulness in various different applications). It then describes the meeting of interested parties that took place in Amsterdam in March 2007, and MMV's role with regard to these drugs once they are in phase 4.
Presentation from ‘Getting antimalarials to patients’. MMV access symposium, Kampala, Uganda, 9 May 2007.